195 related articles for article (PubMed ID: 25635530)
41. Richter syndrome: A rare complication of chronic lymphocytic leukemia or small lymphocytic lymphoma.
Wąsik-Szczepanek E; Szymczyk A; Szczepanek D; Wszoła-Kleinrok J; Chocholska S; Pluta A; Hus M
Adv Clin Exp Med; 2018 Dec; 27(12):1683-1689. PubMed ID: 30156387
[TBL] [Abstract][Full Text] [Related]
42. The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression.
Langerbeins P; Bahlo J; Rhein C; Cramer P; Pflug N; Fischer K; Stilgenbauer S; Kreuzer KA; Wendtner CM; Eichhorst B; Hallek M
Future Oncol; 2015; 11(13):1895-903. PubMed ID: 26161926
[TBL] [Abstract][Full Text] [Related]
43. Disseminated histoplasmosis as pseudo Richter's transformation in a patient with chronic lymphocytic leukemia.
Jain P; Hu S; Jabbour E; Takahashi K; Pemmaraju N; O'Brien S; Mulanovich VE; Estrov Z
Am J Hematol; 2015 Aug; 90(8):752-3. PubMed ID: 25850565
[No Abstract] [Full Text] [Related]
44. Ibrutinib-based therapy impaired neutrophils microbicidal activity in patients with chronic lymphocytic leukemia during the early phases of treatment.
Prezzo A; Cavaliere FM; Bilotta C; Pentimalli TM; Iacobini M; Cesini L; Foà R; Mauro FR; Quinti I
Leuk Res; 2019 Dec; 87():106233. PubMed ID: 31639635
[TBL] [Abstract][Full Text] [Related]
45. Clonal IgH gene rearrangements identify Richter's transformation to diffuse large B cell lymphoma.
Dalela D; Bledsoe JR; Patel SA
Ann Hematol; 2021 Dec; 100(12):3075-3077. PubMed ID: 33159568
[No Abstract] [Full Text] [Related]
46. Ibrutinib-associated oral ulcers.
Thermos G; Tosios KI
Oral Oncol; 2020 Jan; 100():104445. PubMed ID: 31629661
[No Abstract] [Full Text] [Related]
47. Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia.
Bitar C; Farooqui MZ; Valdez J; Saba NS; Soto S; Bray A; Marti G; Wiestner A; Cowen EW
JAMA Dermatol; 2016 Jun; 152(6):698-701. PubMed ID: 26982511
[TBL] [Abstract][Full Text] [Related]
48. Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib.
Gordon MJ; Churnetski M; Alqahtani H; Rivera X; Kittai A; Amrock SM; James S; Hoff S; Manda S; Spurgeon SE; Choi M; Cohen JB; Persky D; Danilov AV
Cancer; 2018 Aug; 124(15):3192-3200. PubMed ID: 29797667
[TBL] [Abstract][Full Text] [Related]
49. Anterior chamber fibrinoid syndrome after cataract extraction in a patient on ibrutinib for B-cell chronic lymphocytic leukemia: a case report and review of the literature.
Kolomeyer AM; Hwang CK; Kim BJ
J Med Case Rep; 2018 Nov; 12(1):349. PubMed ID: 30442199
[TBL] [Abstract][Full Text] [Related]
50. Duvelisib: a new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia.
Frustaci AM; Tedeschi A; Deodato M; Zamprogna G; Cairoli R; Montillo M
Future Oncol; 2019 Jul; 15(19):2227-2239. PubMed ID: 31137964
[TBL] [Abstract][Full Text] [Related]
51. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
Maddocks KJ; Ruppert AS; Lozanski G; Heerema NA; Zhao W; Abruzzo L; Lozanski A; Davis M; Gordon A; Smith LL; Mantel R; Jones JA; Flynn JM; Jaglowski SM; Andritsos LA; Awan F; Blum KA; Grever MR; Johnson AJ; Byrd JC; Woyach JA
JAMA Oncol; 2015 Apr; 1(1):80-7. PubMed ID: 26182309
[TBL] [Abstract][Full Text] [Related]
52. Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre.
Uminski K; Brown K; Bucher O; Hibbert I; Dhaliwal DH; Johnston JB; Geirnaert M; Dawe DE; Banerji V
Curr Oncol; 2019 Oct; 26(5):e610-e617. PubMed ID: 31708654
[TBL] [Abstract][Full Text] [Related]
53. Richter's transformation in the heart.
Marra A; Adamo F; Baldoni S; Laurenti ME; Giansanti M; Pasquino S; Bigerna B; Sorcini D; Stella A; Guarente V; Limongello R; Perriello V; Martino G; Ascani S; Falini B; Sportoletti P
Lancet Oncol; 2021 Jul; 22(7):e341. PubMed ID: 34197763
[No Abstract] [Full Text] [Related]
54. Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Coutré SE; Furman RR; Flinn IW; Burger JA; Blum K; Sharman J; Jones J; Wierda W; Zhao W; Heerema NA; Johnson AJ; Tran A; Zhou C; Bilotti E; James DF; Byrd JC; O'Brien S
Clin Cancer Res; 2017 Mar; 23(5):1149-1155. PubMed ID: 28073846
[No Abstract] [Full Text] [Related]
55. Recurrent Richter's Transformation Presenting With a Penile Ulcer.
Yamany T; Reddy BY; Husain S; Grossman ME
JAMA Dermatol; 2016 May; 152(5):586-7. PubMed ID: 26843375
[No Abstract] [Full Text] [Related]
56. Hodgkin's lymphoma variant of Richter's syndrome.
Vasilj A; Kojić-Katović S; Maricević I; Zokvić E; Kelcec IB; Tomas D; Curić-Jurić S
Coll Antropol; 2010 Mar; 34(1):295-9. PubMed ID: 20437646
[TBL] [Abstract][Full Text] [Related]
57. Richter's syndrome presenting as a nasal lymphoma.
Yamamoto Y; Tsujimoto M; Konoike Y; Nakamine H; Morii T; Kimura H
Leuk Lymphoma; 2004 Sep; 45(9):1919-23. PubMed ID: 15223655
[TBL] [Abstract][Full Text] [Related]
58. IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution.
Mao Z; Quintanilla-Martinez L; Raffeld M; Richter M; Krugmann J; Burek C; Hartmann E; Rudiger T; Jaffe ES; Müller-Hermelink HK; Ott G; Fend F; Rosenwald A
Am J Surg Pathol; 2007 Oct; 31(10):1605-14. PubMed ID: 17895764
[TBL] [Abstract][Full Text] [Related]
59. Survival adjusting for crossover: phase 3 study of ibrutinib
Coutre S; Tedeschi A; Robak T; Barr PM; Owen C; Bairey O; Burger J; Zhou C; Styles L; James DF; Kipps TJ
Haematologica; 2018 Jun; 103(6):e249-e251. PubMed ID: 29170253
[No Abstract] [Full Text] [Related]
60. Richter's syndrome in central nervous system with MYD88L265P and CD79b mutation responded well to ibrutinib containing chemotherapy: a case report and review of the literature.
Wang W; Zhang Y; Zhao D; Zhang W; Zhou D
Ann Hematol; 2022 Aug; 101(8):1869-1872. PubMed ID: 35484253
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
